TY - JOUR
T1 - Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer
AU - Lv, Quanxia
AU - Meng, Ziyuan
AU - Yu, Yuanyuan
AU - Jiang, Feng
AU - Guan, Daogang
AU - Liang, Chao
AU - Zhou, Junwei
AU - Lyu, Aiping
AU - Zhang, Ge
N1 - Funding Information:
Sincere thanks should go to the other academic staff members in Aiping Lu and Ge Zhang?s group at Hong Kong Baptist University. We also thank Hong Kong Baptist University for providing critical comments and technical support. This study was supported by the Hong Kong General Research Fund (HKBU12102914 to Ge Zhang), the Faculty Research Grant of Hong Kong Baptist University (FRG2/12-13/027 to Ge Zhang) and National Natural Science Foundation of China (NSFC 81601929 to Yuanyuan Yu).
PY - 2016/12/14
Y1 - 2016/12/14
N2 - Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significantly high expression level of HER2 protein compared to other subtypes. Therefore, HER2 is an important biomarker and an ideal target for developing therapeutic strategies for the treatment HER2+ BC. In this review, HER2 structure and physiological and pathological roles in HER2+ BC are discussed. Two diagnostic tests, immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), for evaluating HER2 expression levels are briefly introduced. The current mainstay targeted therapies for HER2+ BC include monoclonal antibodies, small molecule tyrosine kinase inhibitors, antibody–drug conjugates (ADC) and other emerging anti-HER2 agents. In clinical practice, combination therapies are commonly adopted in order to achieve synergistic drug response. This review will help to better understand the molecular mechanism of HER2+ BC and further facilitate the development of more effective therapeutic strategies against HER2+ BC.
AB - Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significantly high expression level of HER2 protein compared to other subtypes. Therefore, HER2 is an important biomarker and an ideal target for developing therapeutic strategies for the treatment HER2+ BC. In this review, HER2 structure and physiological and pathological roles in HER2+ BC are discussed. Two diagnostic tests, immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), for evaluating HER2 expression levels are briefly introduced. The current mainstay targeted therapies for HER2+ BC include monoclonal antibodies, small molecule tyrosine kinase inhibitors, antibody–drug conjugates (ADC) and other emerging anti-HER2 agents. In clinical practice, combination therapies are commonly adopted in order to achieve synergistic drug response. This review will help to better understand the molecular mechanism of HER2+ BC and further facilitate the development of more effective therapeutic strategies against HER2+ BC.
KW - Antibody–drug conjugates
KW - Diagnostic tests
KW - HER2 positive breast cancer
KW - Molecular mechanism
KW - Monoclonal antibodies
KW - Small molecular inhibitors
KW - Translational therapy
UR - http://www.scopus.com/inward/record.url?scp=85006823613&partnerID=8YFLogxK
U2 - 10.3390/ijms17122095
DO - 10.3390/ijms17122095
M3 - Review article
C2 - 27983617
AN - SCOPUS:85006823613
SN - 1661-6596
VL - 17
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 12
M1 - 2095
ER -
